PDF) Challenges in standardizing safety assessments of biopharmaceuticals, the case of EPREX Associated Pure Red Cell Aplasia | Toine Pieters - Academia.edu
Immunogenicity and glycosylation: The key issues for biosimilars - ppt video online download
SciELO - Saúde Pública - Hubs to spread technology and save lives Hubs to spread technology and save lives
Zomerportret 1. Huub Schellekens: 'Iedereen moet weer gaan doen waar hij goed in is' | medischcontact
Huub Schellekens | Writers Unlimited
Huub Schellekens – Studium Generale Universiteit Utrecht
PDF) Biosimilar therapeutics—What do we need to consider?
Huub Schellekens - HR Business Partner - Feenstra | LinkedIn
Huub Schellekens, Professor of pharmaceutical biotechnology at Utrecht University: "We need 20 billion doses for the entire world population"
Medicijnen voor derde wereld voor 5 procent van de prijs'
Professor Schellekens maakt medicijnen zelf - Zembla - BNNVARA
Zo kan Nederland zich beter wapenen tegen epidemieën
Huub Schellekens, Professor of pharmaceutical biotechnology at Utrecht University: "We need 20 billion doses for the entire world population"
Opgestapt CBG-lid Huub Schellekens uit forse kritiek op 'de perversies van het systeem' - HUMAN - VPRO
PDF) Immunogenicity of Recombinant Human Interferon Beta-1b in Immune-Tolerant Transgenic Mice Corresponds with the Biophysical Characteristics of Aggregates
Peperduur medicijn voor een schijntje nagemaakt | De Volkskrant
Protection of Rats against Pseudorabies Virus Infection by γ-Interferon
Biosimilars are as safe and efficient for use as cancer medication as the original - News - Utrecht University
Pharmaceutical Technology Europe - August 2010 - What is Hindering the Uptake of Biosimilars
eLearning module: The analytics – Biosimilars: From concern to confidence
Impact of Biosimilar Insulins on Clinical Practice
Huub Schellekens | European Association of Hospital Pharmacists
Zomerportret 1. Huub Schellekens: 'Iedereen moet weer gaan doen waar hij goed in is' | medischcontact
Cv huub schellekens complet by Ricardo Guerrero - Issuu
PDF) Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies
PDF) Immunogenicity of mAbs in non-human primates during nonclinical safety assessment | Beatriz Silva Lima - Academia.edu
